Royalty Pharma Declares Third Quarter 2025 Dividend
NEW YORK, NY, July 18, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.
Investors
Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.
Latest results
Portfolio metrics
35+
Approved products
16
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration
Financial metrics
$2.8bn
Portfolio Receipts
(2024)
(2024)
$2.6bn
Adjusted EBITDA
(2024)
(2024)
$2.4bn
Average annual capital deployed (2019-2024)
$2.8bn
Announced value of transactions (2024)
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q1 2025
Corporate presentation
Latest releases
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
NEW YORK, NY, July 17, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately.
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
NEW YORK, NY, July 16, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open.
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, NY, June 24, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million.
